# Composition and vaccine for treating lung cancer

- **Patent:** US 20160168227
- **Original title:** Composition and vaccine for treating lung cancer
- **Owner:** Curevac AG
- **Status:** Active
- **Times cited:** 80

## What it does

The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5T4 (Trophoblast glycoprotein, TPBG), Survivin (Baculoviral TAP repeat-containing protein 5; BIRC5), NY-ESO-1 (New York esophageal squamous cell carcinoma 1, CTAG1B), MAGE-C1 (Melanoma antigen family C1), MAGE-C2 (Melanoma antigen family C2), and MUC1 (Mucin 1). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (NSCLC), and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and/or the vaccine.

## Frequently asked questions

### Who owns patent US 20160168227?

This patent is owned by Curevac AG.

### When does this patent expire?

This patent is expected to expire on February 19, 2036, when the invention enters the public domain.

### What is patent US 20160168227 cited by?

This patent has been cited by 80 later patents that build on its ideas.

**Full plain-English explainer:** https://patentbrief.org/patent/us/20160168227/composition-and-vaccine-for-treating-lung-cancer

**Original patent:** https://patents.google.com/patent/US20160168227

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._